Disease · MONDO_0000607
Comparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 29
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bexarotene Exposed vs Bexarotene Naive: deaths from any cause | 3 of 79 | 3 of 60 | 139 | NCT00425555 | Trial comparisons |
| Bexarotene Exposed vs Bexarotene Naive: serious adverse events | 33 of 79 | 23 of 60 | 139 | NCT00425555 | Trial comparisons |
| Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): deaths from any cause | 6 of 47 | 5 of 84 | 131 | NCT00007345 | Trial comparisons |
| Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): Number of Participants With Adverse Events | 47 of 47 | 84 of 84 | 131 | NCT00007345 | Trial comparisons |
| Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): serious adverse events | 20 of 47 | 38 of 84 | 131 | NCT00007345 | Trial comparisons |
| Bexarotene 150 mg/m^2/Day vs Bexarotene 300 mg/m^2/Day: serious adverse events | 11 of 30 | 13 of 29 | 59 | NCT01007448 | Trial comparisons |
| Arm A (CTCL, ITT Population) vs Arm B (PTCL, ITT Population): serious adverse events | 7 of 29 | 8 of 24 | 53 | NCT00274651 | Trial comparisons |
| Parts 2 and 3 : Cutaneous T-cell Lymphoma (CTCL) vs Parts 2 and 3: T-cell Lymphoma (TCL): Parts 2 and 3: Overall Response Rate (ORR)-Olsen 2011-Disease Indication | 2 of 21 | 5 of 29 | 50 | NCT02663518 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Not Evaluable (NE) | 4 of 9 | 2 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Progressive Disease (PD) | 2 of 9 | 0 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Partial Response (PR) | 1 of 9 | 1 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Stable Disease (SD) | 2 of 9 | 4 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): deaths from any cause | 3 of 9 | 1 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Complete Response (CR) | 0 of 9 | 0 of 7 | 16 | NCT02314247 | Trial comparisons |
| Selinexor (PTCL) vs Selinexor (CTCL): serious adverse events | 8 of 9 | 1 of 7 | 16 | NCT02314247 | Trial comparisons |
| ECP Pento TBI vs Pento TBI: Overall Survival | 2 of 3 | 5 of 11 | 14 | NCT00402714 | Trial comparisons |
| 1 ECP and Pent/TBI vs 2 Pent/TBI: Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis | 1 of 3 | 8 of 11 | 14 | NCT00402714 | Trial comparisons |
| ECP/Pent vs Pent: serious adverse events | 1 of 3 | 4 of 11 | 14 | NCT00402714 | Trial comparisons |
| Topical Resiquimod 0.06% vs Topical Resiquimod 0.03%: deaths from any cause | 0 of 8 | 0 of 5 | 13 | NCT01676831 | Trial comparisons |
| Topical Resiquimod 0.06% vs Topical Resiquimod 0.03%: serious adverse events | 0 of 8 | 0 of 5 | 13 | NCT01676831 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000607/comparisons